CA-ARIBIO-CO.,-LTD.
31.3.2023 18:01:37 CEST | Business Wire | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFCO Launches TRLLN, a Pioneering Tracking-as-a-Service Solution for Global Asset Visibility18.6.2026 12:55:00 CEST | Press release
TRLLN applies IFCO’s supply chain expertise to help companies address one of logistics’ most persistent challenges: limited visibility across large, fast-moving asset networks. IFCO, a global leader in reusable packaging solutions for the fresh food supply chain, is launching TRLLN (pronounced “trillion”), a standalone technology venture designed to help companies improve visibility across large, fast-moving asset networks. Unlike traditional tracking models that often require gates, scanners, or fixed hardware installations along the supply chain, TRLLN’s infrastructure-free approach allows companies to deploy asset tracking significantly faster and with less operational complexity. TRLLN’s platform addresses four core visibility questions across industries: where the asset is, whether it is in the right condition, whether it has reached the right destination, and what its full movement history shows. While use cases differ by sector, the technology can be applied across a wide range
NIQ and Ogury Collaborate to Enhance Media Planning and Audience Strategy with GeoPurchase Insights18.6.2026 12:00:00 CEST | Press release
New initiative brings real-world retail purchase signals into Ogury’s Persona Intelligence Engine to deliver deeper, privacy preserving insights across North America and Europe NIQ (NYSE: NIQ), the world’s leading consumer intelligence company, today announced a new collaboration with Ogury, the global AdTech company powered by Persona Intelligence. Through the collaboration, Ogury will integrate NIQ’s GeoPurchase data into its Persona Intelligence Engine, strengthening audience planning, media activation, and strategic insights for marketers. NIQ delivers world-leading retail intelligence, capturing actual purchase data at the product level across key retailers around the world. Through this collaboration, NIQ is providing GeoPurchase insights at scale across France, Germany, Spain, Italy, the UK, as well as the United States and Canada, bringing a new layer of real-world retail purchase behavior into Ogury’s Persona Intelligence Engine. Combined with Ogury’s audience-first data model
Linvo Sets Sights on AI-Led Wealth Management, Opens AI Advisor Roles for 202618.6.2026 11:40:00 CEST | Press release
Linvo AG, a Zurich-based multi-family office and wealth management firm, today set out its vision for the year ahead, naming applied artificial intelligence as the centre of its strategy for 2026 and opening a new set of AI advisor roles to deliver it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618933521/en/ Linvo sets sights on AI-led wealth management, opens AI advisor roles for 2026 The firm sees the coming year as the point at which AI moves from a support tool to a core discipline within wealth management — shaping how portfolios are analysed, how clients are served, and how advisory teams spend their time. The new AI advisor roles are intended to anchor that shift inside the firm. "2026 is the year we stop treating AI as an add-on and start treating it as a discipline in its own right," said Alexander Kogan, Director at Linvo. "Hiring AI advisors is how we build that future deliberately, rather than leaving it t
Frost & Sullivan 2026 Technology Innovation Leadership Best Practices Recognition for Ohmium International18.6.2026 10:31:00 CEST | Press release
Ohmium International Inc., a leading manufacturer of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has received the 2026 Global Technology Innovation Leadership Recognition for Best Practices in the PEM electrolyzer and green hydrogen industry by Frost & Sullivan. This recognition highlights Ohmium's continued advancement of cutting-edge PEM technology into scalable, real-world hydrogen solutions that address critical energy and industrial challenges across global markets. Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition for Best Practices to organizations that demonstrate exceptional achievement in leveraging technology to drive market transformation and measurable business impact. The firm evaluates companies across two core dimensions: technology leverage and business impact. Ohmium excelled across both measures, demonstrating commitment to innovation, stage gate efficiency, commercialization, and applic
Infobip Ranked in Top 25 of Fortune's Europe's Most Innovative Companies 202618.6.2026 10:11:00 CEST | Press release
A strong result highlighting Infobip’s momentum in European tech innovation Global AI-first cloud communications platform Infobip has been ranked in the top 25 of Fortune's Europe's Most Innovative Companies 2026, marking a strong rise on this year's list. The announcement was made at VivaTech in Paris. Last year, Infobip entered Fortune's inaugural ranking at number 68. This year, it climbs to 16! The Fortune Europe's Most Innovative Companies list, in partnership with the global research firm Statista, evaluates companies based on innovation culture, product development, and process improvements. Infobip's rise reflects the accelerating momentum behind its AI-first strategy, including the launch of Infobip AgentOS, its AI-native fully managed solution that orchestrates autonomous AI-driven customer journeys at scale. Infobip's innovation credentials are further reinforced by its role in Important Project of Common European Interest (IPCEI) for Next Generation Cloud Infrastructure and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom